T
Todd A. Carter
Researcher at Ambit Biosciences
Publications - 3
Citations - 2083
Todd A. Carter is an academic researcher from Ambit Biosciences. The author has contributed to research in topics: MAPK7 & MAP2K7. The author has an hindex of 3, co-authored 3 publications receiving 1974 citations.
Papers
More filters
Journal ArticleDOI
A small molecule-kinase interaction map for clinical kinase inhibitors.
Miles A. Fabian,William H. Biggs,Daniel K. Treiber,Corey E. Atteridge,Mihai Azimioara,Mihai Azimioara,Michael G. Benedetti,Michael G. Benedetti,Todd A. Carter,Pietro Ciceri,Philip T. Edeen,Mark Floyd,Julia M. Ford,Margaret Galvin,Jay L Gerlach,Jay L Gerlach,Robert M. Grotzfeld,Sanna Herrgard,Darren E. Insko,Michael A Insko,Andiliy G. Lai,Jean-Michel Lélias,Shamal A. Mehta,Zdravko V. Milanov,Anne Marie Velasco,Lisa M. Wodicka,Hitesh K. Patel,Patrick P. Zarrinkar,David J. Lockhart +28 more
TL;DR: An efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases is described, which represents a systematic small molecule-protein interaction map for clinical compounds across a large number of related proteins.
Journal ArticleDOI
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
Qi Chao,Kelly G. Sprankle,Robert M. Grotzfeld,Andiliy G. Lai,Todd A. Carter,Anne Marie Velasco,Ruwanthi N. Gunawardane,Merryl D. Cramer,Michael F. Gardner,Joyce James,Patrick P. Zarrinkar,Hitesh K. Patel,Shripad Bhagwat +12 more
TL;DR: Compound 7 (AC220) was identified from this series to be the most potent and selective FLT3 inhibitor with good pharmaceutical properties, excellent PK profile, and superior efficacy and tolerability in tumor xenograft models.
Journal ArticleDOI
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.
Hitesh K. Patel,Robert M. Grotzfeld,Andiliy G. Lai,Shamal A. Mehta,Zdravko V. Milanov,Qi Chao,Kelly G. Sprankle,Todd A. Carter,Anne Marie Velasco,Miles A. Fabian,Joyce James,Daniel K. Treiber,David J. Lockhart,Patrick P. Zarrinkar,Shripad Bhagwat +14 more
TL;DR: A series of diaryl ureas with an amide substitution at the 4-position was prepared and found to be potent and selective FLT3 inhibitors with good oral bioavailability and efficacy in a tumor xenograft model.